纳武利尤单抗治疗患者的免疫相关关节炎FDG PET/CT表现
本文报告一例56岁原发性恶性黑色素瘤女性患者,接受纳武利尤单抗治疗5个月后行全身FDG PET/CT评估疗效,发现四肢主要关节代谢活性增高,与既往PET/CT相比为新发表现,判读为免疫相关关节炎并发症。
要点
- 免疫检查点抑制剂治疗中可出现免疫相关关节炎。
- 纳武利尤单抗治疗后FDG PET/CT示四肢主要关节代谢增高。
- 该表现与既往PET/CT相比为新发,判读为免疫相关关节炎并发症。
核心结论
- 纳武利尤单抗治疗5个月后全身FDG PET/CT示四肢主要关节代谢活性增高,与既往FDG PET/CT相比为新发表现,判读为免疫相关关节炎并发症。
研究设计与样本
- 本文为影像病例报告,对象为1例56岁原发性恶性黑色素瘤女性患者。
主要发现
- 该患者接受纳武利尤单抗治疗5个月,治疗后行全身FDG PET/CT评估疗效。
- FDG PET/CT示四肢主要关节代谢活性增高,与既往FDG PET/CT相比为新发表现。
- 该表现判读为免疫相关关节炎并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors are a new and different treatment option in many of solid tumors, but with many recognized immune-related adverse side effects. In this interesting image, we are presenting a 56-year-old woman with primary malignant melanoma who underwent nivolumab therapy for 5 months, and a posttreatment whole-body FDG PET/CT scan for treatment response evaluation demonstrated increased metabolic activity in the entire major joints of the upper and lower extremities. This was a new finding compared with previous FDG PET/CT scan and was interpreted as an immune-related arthritis complication.
引用
- Bayat M, Doroudinia A, Karam MB, et al. FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab. Clin Nucl Med. 2022. PMID: 36252811. doi:10.1097/RLU.0000000000004429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。